Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EHRs A Vehicle For Delivering REMS Data To Physicians – FDA’s Woodcock

Executive Summary

PHILADELPHIA – FDA is looking at electronic health records to serve as a vehicle for pushing details of Risk Evaluation and Mitigation Strategies to physicians, FDA Center for Drug Evaluation and Research Director Janet Woodcock said.

You may also be interested in...

EHRs A Tool For Drug Label Communications, Adverse Event Reporting And Adherence – FDA’s Woodcock

FDA’s vision for electronic health records is being incorporated into a new application launched by PDR Network.

Sentinel Initiative Needs Better Defined Goals, Outside Review Concludes

The Pharmacovigilance Review Subcommittee of FDA's Science Board reports a lack of clarity within CDER over just what purpose the drug safety program is supposed to serve.

FDA's Chicken Or Egg Question For Pharmacy Leaflets: Should Benefit Or Risk Come First?

FDA will look at which should come first – benefits or risks – when it studies patients' response to three one-page prototypes of patient medication information.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts